Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 43

1.

Hypertonic saline for cystic fibrosis.

Kuver R, Lee SP.

N Engl J Med. 2006 Apr 27;354(17):1848-51; author reply 1848-51. No abstract available.

PMID:
16642591
2.

Inhaled hypertonic saline as a therapy for cystic fibrosis.

Elkins MR, Bye PT.

Curr Opin Pulm Med. 2006 Nov;12(6):445-52. Review.

PMID:
17053496
3.

Altering airway surface liquid volume: inhalation therapy with amiloride and hyperosmotic agents.

Hirsh AJ.

Adv Drug Deliv Rev. 2002 Dec 5;54(11):1445-62. Review.

PMID:
12458154
4.

[Inhaled therapies for cystic fibrosis].

Lahzami S, Nicod LP.

Rev Med Suisse. 2011 Nov 23;7(318):2285-8. Review. French.

PMID:
22400363
5.

Timing of hypertonic saline inhalation for cystic fibrosis.

Elkins M, Dentice R.

Cochrane Database Syst Rev. 2012 Feb 15;(2):CD008816. doi: 10.1002/14651858.CD008816.pub2. Review.

PMID:
22336853
6.

Rationale for hypertonic saline therapy for cystic fibrosis lung disease.

Tarran R, Donaldson S, Boucher RC.

Semin Respir Crit Care Med. 2007 Jun;28(3):295-302. Review.

PMID:
17562499
7.

Inhaled mannitol in cystic fibrosis.

Wills PJ.

Expert Opin Investig Drugs. 2007 Jul;16(7):1121-6. Review.

PMID:
17594195
8.

Inhaled mannitol for the treatment of cystic fibrosis.

Hurt K, Bilton D.

Expert Rev Respir Med. 2012 Feb;6(1):19-26. doi: 10.1586/ers.11.87. Review.

PMID:
22283575
9.

Effect of inhaled dry powder mannitol on mucus and its clearance.

Daviskas E, Rubin BK.

Expert Rev Respir Med. 2013 Feb;7(1):65-75. doi: 10.1586/ers.12.72. Review.

PMID:
23362816
10.

Hypertonic saline in treatment of pulmonary disease in cystic fibrosis.

Reeves EP, Molloy K, Pohl K, McElvaney NG.

ScientificWorldJournal. 2012;2012:465230. doi: 10.1100/2012/465230. Epub 2012 May 3. Review.

11.

Pharmacologic agents for mucus clearance in bronchiectasis.

Nair GB, Ilowite JS.

Clin Chest Med. 2012 Jun;33(2):363-70. doi: 10.1016/j.ccm.2012.02.008. Epub 2012 Apr 6. Review.

PMID:
22640851
12.

Hypertonic saline treatment of cystic fibrosis.

Taylor LM, Kuhn RJ.

Ann Pharmacother. 2007 Mar;41(3):481-4. Epub 2007 Feb 27. Review.

PMID:
17327291
13.
14.

Pharmacotherapy of impaired mucociliary clearance in non-CF pediatric lung disease. A review of the literature.

Boogaard R, de Jongste JC, Merkus PJ.

Pediatr Pulmonol. 2007 Nov;42(11):989-1001. Review.

PMID:
17902149
15.

Hyperosmolar agents and clearance of mucus in the diseased airway.

Daviskas E, Anderson SD.

J Aerosol Med. 2006 Spring;19(1):100-9. Review.

PMID:
16551221
16.

Other medications for aerosol delivery.

Rubin BK.

Paediatr Respir Rev. 2006;7 Suppl 1:S76-9. Epub 2006 Jun 5. Review.

PMID:
16798603
17.

Inhaled adrenergics and anticholinergics in obstructive lung disease: do they enhance mucociliary clearance?

Restrepo RD.

Respir Care. 2007 Sep;52(9):1159-73; discussion 1173-5. Review.

18.

Primary ciliary dyskinesia: prospects for new therapies, building on the experience in cystic fibrosis.

Amirav I, Cohen-Cymberknoh M, Shoseyov D, Kerem E.

Paediatr Respir Rev. 2009 Jun;10(2):58-62. doi: 10.1016/j.prrv.2008.11.003. Epub 2009 Apr 9. Review.

PMID:
19410203
19.

The epithelium as a target for therapy in cystic fibrosis.

Thelin WR, Boucher RC.

Curr Opin Pharmacol. 2007 Jun;7(3):290-5. Epub 2007 May 1. Review.

PMID:
17475561
20.

Amiloride for lung disease in cystic fibrosis.

Zahaykevich A.

DICP. 1991 Dec;25(12):1340-1. Review. No abstract available.

PMID:
1815431

Supplemental Content

Support Center